Hikma Pharmaceuticals (OTCMKTS:HKMPF) Trading Down 9.2% - Here's Why

Key Points

• Hikma Pharmaceuticals' shares dropped 9.2%, trading as low as $23.96, with a significant increase in trading volume compared to the average.
• BNP Paribas has issued an "outperform" rating for Hikma Pharmaceuticals, indicating a positive outlook despite the recent decline in stock price.
• The company's financial metrics include a current ratio of 1.14 and a debt-to-equity ratio of 0.28, reflecting a relatively stable financial position overall.

Shares of Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - Get Free Report) dropped 9.2% on Wednesday . The company traded as low as $23.96 and last traded at $23.96. Approximately 300 shares were traded during trading, an increase of 307% from the average daily volume of 74 shares. The stock had previously closed at $26.38.

Analyst Upgrades and Downgrades

Separately, BNP Paribas assumed coverage on Hikma Pharmaceuticals in a research note on Tuesday, May 13th. They set an "outperform" rating on the stock.

Hikma Pharmaceuticals Price Performance

The company has a current ratio of 1.14, a quick ratio of 0.65 and a debt-to-equity ratio of 0.28. The stock has a fifty day moving average of $27.29 and a 200 day moving average of $27.04.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.